MSD, Pfizer try to stop three Steglatro generics
29-03-2022
AstraZeneca, MSD sue MSN and Sandoz over Calquence generics
08-02-2022
05-04-2022
Atmosphere1 / Shutterstock.com
Merck Sharp & Dohme (known as MSD outside the US) has filed a complaint against New Dehli-based Mankind Pharma, looking to halt the approval of a generic version of the type two diabetes treatment, Januvia (Sitagliptin).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
MSD, Mankind Pharma, US District Court for the District of Delaware, ANDA, Januvia